重大公告

Announcements

Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to TFDA

1.Date of occurrence of the event:2022/09/12 2.New drug name or code:Bispecific Antibody, AP203 3.Indication:Bispecific antibody AP203 is a second-generation cancer immunotherapy developed by AP Biosciences …

Announcements

Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP203, has been granted by US FDA

1.Date of occurrence of the event:2022/09/10 2.New drug name or code:Bispecific Antibody, AP203 3.Indication:Bispecific antibody AP203 is a second-generation cancer immunotherapy developed by AP Biosciences …

Announcements

Announcement on behalf of AP Biosciences that preemptive rights forfeited by all directors are over 50% and made available to specific persons

1.Date of occurrence of the event:2022/08/31 2.Reason for the forfeiture of subscription rights by the directors nd supervisors: In accordance with related laws and regulations, …

Announcements

Announcement on behalf of AP Biosciences’ call period of 2022 cash capital increase

1.Date of occurrence of the event:2022/08/31 2.Company name:AP Biosciences Inc. (Hereinafter referred to as APBio) 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Subsidiaries …

Announcements

Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to US FDA

1.Date of occurrence of the event:2022/08/12 2.New drug name or code:Bispecific Antibody, AP203 3.Indication:Bispecific antibody AP203 is a second-generation cancer immunotherapy developed by AP Biosciences …